Gastrointestinal disease drug developer Phathom raised almost $182m in an initial public offering that involved Takeda bumping up its equity stake in the company.

GSK and Merck Group-backed Progyny floated in an offering that involved the fertility benefits manager pricing its shares below their range.

Dahong Group, Junfa Group, Prosperity Holdings and Yintai Land are all in line for exits after the workspace provider confidentially filed for an initial public offering in the US.

The Celgene and GV-backed cancer and atopic dermatitis drug developer is now targeting $75m in an initial public offering it postponed in August.

Emtek, which had planned to sell as much as $55m worth of shares, will have to wait longer for an exit after the real estate marketplace withdrew from the proposed offering.

Takeda is set to emerge with almost 26% of Phathom Pharmaceuticals, which has licensed one of its gastrointestinal disease drugs, and which is targeting $158m.

ProMedica and Pacira are both in line for exits after surgical implant producer Tela Bio filed for an initial public offering.

SoftBank Vision Fund-backed immunology therapy developer Vir will float at the bottom of its range, having raised in excess of $820m in VC funding in roughly three years.

Online real estate marketplace Fangdd has filed for a $150m initial public offering that would allow Shanying International to exit.

Johannes Gutenberg University of Mainz's cancer therapy developer raised $150m despite reducing the number of shares in the IPO and floating beneath its range.